Zepbound (tirzepatide ... researchers found that tirzepatide in doses of 5, 10, and 15 milligrams (mg) resulted in significant and sustained weight loss. The study, which had support from the ...

Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the pharmaceutical giant is one of the ...

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

On Tuesday, the agency gave the green light for Ozempic to help protect kidney function in people with diabetes and Zepbound as the first-ever drug treatment for sleep apnea in people with obesity.

The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk ... market will be worth $33.7 billion. The near-10% compound annual growth rate predicted by the ...

The stock stumbled in October last year, after Zepbound's sales disappointed ... much higher than peers Merck & Co and Pfizer's 10.72 and 9.07, respectively.

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...

Even with Eli Lilly's Mounjaro and Zepbound not growing as fast as many ... analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn ...